Original Research Article

Adequate timing of thromboembolic prophylaxis in colorectal cancer surgery

Ghada Morshed*, Nader Zaki

Department of Surgery, Faculty of Medicine Fayoum University, Fayoum, University, Cairo, Egypt

Received: 28 November 2017
Received: 30 December 2017
Accepted: 03 January 2018

*Correspondence:
Dr. Ghada Morshed,
E-mail: ghadamorshed@yahoo.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: It has been found that patients with colorectal cancer are at increased risk for postoperative venous thromboembolism. The aim of this prospective study is to evaluate the incidence of venous thromboembolism and major bleeding complications in patients undergoing colorectal cancer who are treated with preoperative or postoperative venous thromboprophylaxis.

Methods: This prospective study included 30 patients from September 2013 to November 2017. There were 22 males and 8 females; mean age was 66.7±5.5 years (range 44-78). Author divided the patients randomly into two groups (group A=15 cases with preoperative and group B = 15 cases with postoperative venous thromboprophylaxis).

Results: There was no significant difference in preoperative versus postoperative thromboembolic prophylaxis regarding postoperative DVT 0/15(0%) vs 1/15 (6.6%), P=0.69, no bleeding complications and no pulmonary embolism.

Conclusions: Preoperative and postoperative thromboembolic prophylaxis are equally safe in venous thromboembolism protection.

Keywords: Bleeding complications, Colorectal cancer, Thromboembolic prophylaxis

INTRODUCTION

It has been found that colorectal cancer patients are at increased risk for venous thromboembolism VTE post discharge, and both chest guidelines and the national comprehensive cancer network to recommend postoperative VTE prophylaxis for 4 weeks.1

Postoperative venous thromboembolism may be due to patient risk factors.

Patients with inflammatory bowel disease have twice the risk compared with the general population of VTE, may be due to severity of disease activity.2

The peak of VTE risk approximately 3 weeks post-surgery and increased up to 12 weeks post-surgery.3 So extended prophylaxis regimens are recommended.4,5

Venous thromboprophylaxis is accompanied with risk of bleeding. As demonstrated by ACCP and SCIP guidelines, there is no consensus timing of VTE prophylaxis post major colorectal surgery.

The aim of this prospective study is to evaluate the incidence of venous thromboembolism and major bleeding complications in patients undergoing colorectal cancer who are treated with preoperative or postoperative venous thromboprophylaxis.
METHODS

This prospective study included included 30 patients with colorectal cancer stage I-III from September 2013 to August 2017. There were 22 males and 8 females, mean age was 66.7±5.5 years (range 44-78). Author divided the patients randomly into two groups (group A=15 cases with preoperative venous thromboprophylaxis clexane 40mg the day before surgery once) and (group B = 15cases with postoperative venous thromboprophylaxis with clexane 40mg once /day for 4 weeks). All patients were instructed to full mobilization postoperatively. Venous duplex was performed for all patients immediately before surgery to detect occult preoperative deep vein thrombosis.

Authors included patients undergoing colorectal cancer surgery via laparotomy. Authors excluded pregnant females, current DVT, patients with active or recent haemorrhage and patients with anticoagulation therapy. Authors measured early (48-hrs) and overall (4 weeks) postoperative venous thromboembolism VTE by duplex sonography, high probability on ventilation-perfusion scan and bleeding complications in the form of bleeding from any site, operative site bleeding, intraocular or intracranial hemorrhage, upper or lower gastrointestinal hemorrhage ecchymosis or epistaxis.

The study was approved by the ethical committee of El Fayoum University Hospital. Informed consent was obtained from all individual participants included in the study.

Results are expressed as Mean±SD. Significance is obtained with Analysis of Variance (ANOVA). Chi - square test was used to detect degree of variability and a value of p <0.05 is considered statistically significant.

RESULTS

All patients with occult deep venous thrombosis were excluded from the study, this prospective study included 30 patients from September 2013 to November 2017. There were 22 males and 8 females; mean age was 66.7±5.5 years (range 44-78) (Table 1).

| Data | Thromboembolic prophylaxis | P value |
|------|----------------------------|---------|
|      | Preoperative | Postoperative |         |
| Postoperative DVT | 0/15(0%) | 1/15 (6.6%) | 0.69   |
| Bleeding complications | No | No |         |
| Pulmonary embolism | No | No |         |
| Postoperative anastomotic leakage | No | No |         |

DISCUSSION

It has been found that the incidence of venous thromboembolism VTE post colorectal surgery with perioperative venous thromboprophylaxis ranges from 9 to 20%.6 Also it has been found that patients with colorectal cancer are at increased risk for postoperative venous thromboembolism with incidence rate from 37% to 46%, respectively.7

Malignancy is associated with increased risk factor of higher VTE rates.8 Other risk factors patient-related and procedure-related such as open surgery, obesity, emergency operations, American Society of Anesthesiologists class, have been associated with VTE in some series but not in others.8,16 VTE prophylaxis in abdominal or pelvic surgery patients with cancer perioperatively and extended postoperatively reduces overall VTE and VTE-related complications.17,18

In present study author gave thromboembolic prophylaxis for patients preoperatively and extended 4 weeks postoperatively without minor or major postoperative haemorrhage like other study with follow up 30 days post-surgery.19

There was no significant difference in preoperative versus postoperative thromboembolic prophylaxis regarding postoperative DVT 0/15(0%) vs 1/15 (13.3%); P = 0.69, and the suspected cause in the case who developed DVT one week postoperatively due to immobilization and obesity inspite of postoperative
venous thromboembolic prophylaxis like other study with venous thromboembolic prophylaxis given within 24 hours of colorectal cancer surgery showing lowest rates of adverse events and other study showed that both unfractionated heparin and low-molecular-weight heparin can effectively reduce the incidence of venous thromboembolism in colorectal cancer surgery.20,21

CONCLUSION

There was no significant difference in preoperative versus postoperative thromboembolic prophylaxis in colo-rectal cancer surgery regarding postoperative DVT, pulmonary embolism or haemorrhage and it is safe to extend postoperative prophylaxis for 4 weeks.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Gould MK, Garcia DA, Wren SM. Prevention of VTE in non-orthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th Ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e227S-77.
2. Merril A, Millham F. Increased risk of postoperative deep vein thrombosis and pulmonary embolism in patients with inflammatory bowel disease. Arch Surg. 2012;147:120-4.
3. Sweetland S, Green J, Liu B. Million Women Study Collaborators. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ. 2009;339:b4583.
4. Bergqvist D, Agnelli G, Cohen AT. Enoxacan II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975-80.
5. Vedovati MC, Becattini C, Rondelli F. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg. 2014;259(4):665-9.
6. McLeod RS, Geerts WH, Sniderman KW, Greenwood C, Gregoire RC, Taylor BM, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg. 2001;233(3):438.
7. Heit JA, O’Fallon WM, Petterson TM. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch Intern Med. 2002;162:1245-8.
8. Agnelli G, Bolis G, Capussotti L. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243(1):89-95.
9. Monn MF, Haut ER, Lau BD. Is venous thromboembolism in colorectal surgery patients preventable or inevitable? One institution’s experience. J Am Coll Surg. 2013;216(3):395-401.
10. Fleming FJ, Kim MJ, Salloum RM. How much do we need to worry about venous thromboembolism after hospital discharge? a study of colorectal surgery patients using the National Surgical Quality Improvement Program database. Dis Colon Rectum. 2010;53(10):1355-60.
11. Henke PK, Arya S, Panucci C. Procedure-specific venous thromboembolism prophylaxis: a paradigm from colectomy surgery. Surg. 2012;152(4):528-34.
12. Shapiro R, Vogel JD, Kiran RP. Risk of postoperative venous thromboembolism after laparoscopic and open colorectal surgery: an additional benefit of the minimally invasive approach? Dis Colon Rectum. 2011;54(12):1496-502.
13. Greenblatt DY, Rajamanickam V, Pugely AJ. Short-term outcomes after laparoscopic-assisted proctectomy for rectal cancer: results from the ACS NSQIP. J Am Coll Surg. 2011;212(5):844-54.
14. Sulu B, Aytaç E, Stocchi L, Vogel JD. The minimally invasive approach is associated with reduced perioperative thromboembolic and bleeding complications for patients receiving preoperative chronic oral anticoagulant therapy who undergo colorectal surgery. Surg Endosc. 2013;27(4):1339-45.
15. Merkow RP, Biliomoria KY, McCarter MD. Effect of body mass index on short-term outcomes after colectomy for cancer. J Am Coll Surg. 2009;208(1):53-61.
16. Mustain WC, Davenport DL, Hourigan JS Obesity and laparoscopic colectomy: outcomes from the ACS-NSQIP database. Dis Colon Rectum. 2012;55(4):429-35.
17. Kakkar VV, Balibrea JL, Martínez-González J CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost. 2010;8(6):1223-9.
18. Leonardi MJ, McGory ML, Ko CY. A systematic review of deep venous thrombosis prophylaxis in cancer patients: implications for improving quality. Ann Surg Oncol. 2007;14(2):929-36.
19. Zaghiyan KN, Sax HC, Mirafiori E. Timing of Chemical Thromboprophylaxis and Deep Vein Thrombosis in Major Colorectal Surgery: A Randomized Clinical Trial. Ann Surg. 2016;264(4):632-9.
20. Steve Kwon. Meissner M. Rebecca Symons. J Am Coll Surg. 2011;213:596-603.
21. Bergqvist D. Venous Thromboembolism: A review of risk and prevention in colorectal surgery patients. Dis Colon Rectum. 2006;49(10):1620-8.

Cite this article as: Morshed G, Zaki N. Adequate timing of thromboembolic prophylaxis in colorectal cancer surgery. Int Surg J 2018;5:576-9.